Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

  • Alimujiang, S. (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Zhang, Tao (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Han, Zhi-Gang (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Yuan, Shuai-Fei (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Wang, Qiang (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Yu, Ting-Ting (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University) ;
  • Shan, Li (Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical University)
  • Published : 2013.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Use of epidermal growth factor receptor inhibitors (EGFR-TKIs ) is now standard for non-small-cell lung cancer (NSCLC). However, the effects of EGFR-TKIs in maintenance therapy for advanced NSCLC patients are still unclear. The preent meta-analysis was performed to examine pooled data of randomized control trials (RCT) where EGFR-TKIs were compared against placebo in maintenance regimens for patients with advanced NCSLC to quantify potential benefits and determine safety. Methods: Several data bases were searched, including PubMed, EMBASE and CENTRAL, and we performed an internet search of conference literature. The endpoints were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS). We performed a meta-analysis of the published data, using Comprehensive Meta Analysis software (Version 2.0). with a fixed effects model and an additional random effects model, when applicable. The results of the meta-analysis are expressed as hazard ratios (HRs) or risk ratios (RRs), with their corresponding 95% confidence intervals (95%CIs). Results: The final analysis included six trials, covering 3,758 patients. Compared with placebo, EGFR-TKIs maintenance therapy improved ORR and PFS for patients with advanced NSCLC, the difference being statistically significant (P<0.05), but proved unable to prolong patients' OS. The main adverse reactions were diarrhea and rashes. Conclusion: EGFR-TKIs demonstrated encouraging efficacy, safety and survival when delivered as maintenance therapy for patients with advanced NSCLC after first-line chemotherapy, especially for the patients who had adenocarcinomas, were female, non-smokers and patients with EGFR gene mutations.

Keywords

References

  1. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG (2012). Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract, 18, 12-8. https://doi.org/10.1111/j.1365-2753.2010.01516.x
  2. Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised, placebo cont-rolled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  3. Ciardiello F, Tortora G (2008). EGFR antagonists in cancer treatment. New Engl J Med, 358, 1160-74. https://doi.org/10.1056/NEJMra0707704
  4. Cohen MH, Johnson JR, Chattopadhyay S,et al (2010). Approval summary: erlotinib maintenance therapy of advanced/ metastatic non-small cell lung cancer (NSCLC). Oncologist, 15, 1344-51. https://doi.org/10.1634/theoncologist.2010-0257
  5. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  6. Gaafar RM, Surmont VF, Scagliotti GV, et al (2011). A doubleblind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advan-ced NSCLC, nonprogressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer, 47, 2331-40. https://doi.org/10.1016/j.ejca.2011.06.045
  7. Galetta D, Rossi A, Pisconti S, Millaku A, Colucci G (2010). Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. Cancer Treat Rev, 36, 30-3. https://doi.org/10.1016/S0305-7372(10)70017-7
  8. Gatzemeier U, Pluzanska A, Szczesna A, et al (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25, 1545-52. https://doi.org/10.1200/JCO.2005.05.1474
  9. Grossi F, Aita M, Foilador A, et al (2007). Sequential, alternating, and maintenance /consolidation chemotherapy in advanced non-small cell lung cancer: a review for the literature. Oncologist, 12, 451-64. https://doi.org/10.1634/theoncologist.12-4-451
  10. Herbst RS, Prager D, Hermann R, et al (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 23, 5892-9. https://doi.org/10.1200/JCO.2005.02.840
  11. Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4. https://doi.org/10.7314/APJCP.2012.13.4.1281
  12. Kelly K, Chansky K, Gaspar LE, et al (2008). Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 26, 2450-6. https://doi.org/10.1200/JCO.2007.14.4824
  13. Lee SM, Khan I, Upadhyay S, et al (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebocontrolled, phase 3 trial. Lancet Oncol, 13, 1161-70. https://doi.org/10.1016/S1470-2045(12)70412-6
  14. Liu HB, Wu Y, Lv TF, et al (2013). Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One, 8, e55128. https://doi.org/10.1371/journal.pone.0055128
  15. Lu S, Yu YF (2011). Maintenance Therapy for NSCLC: Consensus and Controversy. Chin J Cancer Res, 23, 254-8. https://doi.org/10.1007/s11670-011-0254-5
  16. Miller VA, O'Connor P, Soh C, et al (2009). For the ATLAS Investigators: A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 27, 18s https://doi.org/10.1200/JCO.2009.22.4626
  17. Mok TS, Wu YL, Zhou C, et al (2009). Randomized, placebocontrolled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-smallcell lung cancer. J Clin Oncol, 27, 5080-7. https://doi.org/10.1200/JCO.2008.21.5541
  18. Novello S, Milella M, Tiseo M, et al (2011). Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res, 30, 50. https://doi.org/10.1186/1756-9966-30-50
  19. Ozkaya S, Findik S, Dirican A, Atici AG (2012). Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med, 4, 1035-8.
  20. Perol M, Arpin D (2011). Maintenance therapy in advanced non-small cell lung cancer: A new paradigm? Presse Med, 40, 404-14. https://doi.org/10.1016/j.lpm.2011.01.009
  21. Perol M, Chouaid C, Perol D, et al (2012). Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 30, 3516-24. https://doi.org/10.1200/JCO.2011.39.9782
  22. Quan L, Chen W, Shu Y (2010). Current status and prospects of maintenance therapy in advanced stage non-small cell lung cancer. Chin J Lung Cancer, 13, 637-41.
  23. Reckamp KL (2012). Is benefit of maintenance therapy for NSCLC best defined by progression-free survival? Lancet Oncol, 13, 435-6. https://doi.org/10.1016/S1470-2045(12)70157-2
  24. Rinaldi M, Belvedere O, Cauchi C, et al (2006). Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol, 17, 67-70.
  25. Takeda K, Hida T, Sato T, et al (2010). Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol, 28, 753-60. https://doi.org/10.1200/JCO.2009.23.3445
  26. Velez M, Arango BA, Perez CA, Santos ES (2012). Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol, 6, 117-24 .
  27. Wu YL, Kim JH, Park K, et al (2012). Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung cancer, 77, 339-45. https://doi.org/10.1016/j.lungcan.2012.03.012
  28. Xiao H, Ding J, Gao S, Yang S, Huang Y (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.
  29. Yuan DM, Wei SZ, Lu YL, et al (2012). Single-agent maintenance therapy in non-small cell lung cancer: a systematic review and meta-analysis. Chin Med J (Engl), 125 , 3143-9.
  30. Zhang L, Ma S, Song X, et al (2012). Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-celllung cancer (INFOR M, C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol, 13 ,466-75. https://doi.org/10.1016/S1470-2045(12)70117-1

Cited by

  1. Does Sunlight Exposure Improve Survival in Patients with Non-small Cell Lung Cancer? vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6301
  2. Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7195
  3. High Feasibility of Liquid-Based Cytological Samples for Detection of EGFR Mutations in Chinese Patients with NSCLC vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7885
  4. Retrospective Study of ALK Rearrangement and Clinicopathological Implications in Completely Resected Non-small Cell Lung Cancer Patients in Northern Thailand: Role of Screening with D5F3 Antibodies vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3057
  5. Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3419
  6. Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3447
  7. The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review vol.16, pp.6, 2014, https://doi.org/10.1007/s11912-014-0390-4
  8. Maintenance therapy in non-small cell lung cancer vol.15, pp.7, 2015, https://doi.org/10.1586/14737140.2015.1052410
  9. Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
  10. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4439
  11. Verification of the Correlation between Progression-free Survival and Overall Survival Considering Magnitudes of Survival Post-progression in the Treatment of Four Types of Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1001
  12. RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials vol.11, pp.1, 2016, https://doi.org/10.1007/s11523-015-0376-7
  13. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-2873-2